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We have studied the effect of intraperitoneal nitroprusside on small (urea) and middle
(vitamin B12) molecule dialysis clearances in patients maintained on chronic peritoneal dialy-
sis. Clearances were measured in six patients during the addition of 6 mg of nitroprusside to
three and seven consecutive, hourly two-liter exchanges during the course of a routine dialysis
treatment. Results indicate that clearances ofureaand B,2 both increased about 35 percent with
the addition ofthe vasodilator for three exchanges. Clearances immediately returned to baseline
values when administration of the vasodilator was discontinued. Addition of the drug to seven
consecutive exchanges resulted in a sustained 35 percent increment in clearances.
We conclude that addition of6 mg of nitroprusside to peritoneal dialysis solution can result
in a significant increment in both small and middle molecule clearances. Maintenance of the
higher clearances requires sustained administration of the drug, which can be tolerated for at
least six exchanges with no adverse side effects.
INTRODUCTION
During the past few years, maintenance peritoneal dialysis has been utilized
increasingly as a therapeutic modality for patients with end-stage renal disease. A
major limitation of this therapy is the long duration of treatment required to achieve
satisfactory clinical results [1]. Attention has been focused, therefore, on findingways
to increase the rates of solute removal and thus perhaps decrease the time required
for maintenance dialysis therapy [2-6]. For example, the intraperitoneal instillation
of vasodilators during peritoneal dialysis has been clearly shown to result in
significant increments in small molecular clearances in patients [2] and both small
and middle molecule clearances in laboratory animals [4].
The present study was undertaken to obtain data on the effect of intraperitoneal
nitroprusside on small and middle molecule clearances in patients maintained on
chronic peritoneal dialysis. Previous studies in the rat [4] demonstrate a proportional
increase of small and middle size molecules. While Nolph has reported an increase in
small molecule clearances in patients treated with intraperitoneal nitroprusside [14],
a systematic evaluation of middle size molecules has not been performed. Since
molecules in the 300-5000 dalton range may be important mediators ofuremia, this
study was undertaken to measure the effect of intraperitoneal nitroprusside on
middle molecule clearances. While other vasodilators have been used in experimental
dialysis including isoproterenol [3], hydralazine [2], phentolamine [2], dopamine [3],
histamine [4], and bradykinin [4], nitroprusside has been demonstrated to be safe in
humans and was chosen for study. Specifically, dialysis clearances ofurea (MW 60)
and vitamin B12 (MW 1350) were measured during the addition of nitroprusside to
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three and seven consecutive two-liter exchanges during the course of a routine
maintenance dialysis treatment.
METHODS
Six medically stable patients with end-stage renal failure, who were maintained on
chronic peritoneal dialysis via an indwelling two-cuff Tenckhoff catheter for a mean
± SE duration of 17 ±4 months, were studied. No patients had positive peritoneal
dialysis fluid cultures at the time of or in the four months prior to the study. Each
patient was dialyzed for 24- or 36-hour periods and received 36 to 48 hours of
peritoneal dialysis each week.
Commercially available bottled 1.5 percent dextrose dialysate (Travenol) was used
throughout the study and maintained at 370 C by a constant temperature bath. One-
hour exchanges of 2 liters each were used. Each peritoneal clearance determination
was made with an exchange consisting of 10 minutes' inflow time, 30 minutes' dwell
time, and 20 minutes' drain time, as described previously [7-9]. Exchanges were
considered to be technically acceptable for clearance calculations if the 2000 ml
inflow was achieved in ten minutes, there was no significant leakage offluid about the
catheter exit site, and dialysate return measured 1900-2300 ml.
At the start of each dialysis a blood sample was collected and analyzed for B,2
binding protein [10,11]. Previous studies [7] indicated that the level of B12 binding
protein did not change during the course ofan individual peritoneal dialysis. 0.5 mg
ofvitamin B12 was then given intramuscularly; this amount was found to give plasma
B,2 levels that exceeded the level of plasma B,2 binding protein by a factor offour to
ten for the duration of dialysis.
Blood samples were obtained at the midpoint ofeach clearance period. At theend
ofeach exchange, the drainage bag was vigorously shaken and an aliquot ofdialysate
was obtained. Blood and dialysate samples were analyzed for urea [12], and B12
concentrations [13].
Urea and vitamin B12 clearances were calculated using the standard formula [5]
C= clearance (ml/min) Cd x Vd
t x Cb
where Cd = concentration of solute in dialysis drainage fluid, Vd = volume ofdialysis
drainage fluid, t = time of one exchange, Cb = concentration of solute in serum
during the exchange. In the clearance calculation the level ofB12 bindingprotein, and
hence bound B12, was subtracted from the total level of serum B12. B12 binding
protein in dialysate was found to be unmeasurable and hence all of the B12 in the
dialysate was considered unbound. As previously reported [7], recovery rates of
vitamin B12 from 1.5 percent dextrose dialysate were between 95 percent and 105
percent over the range of dialysate B12 concentrations observed in the study.
Since previous studies by our group have shown that from the seventh to the thirty-
sixth exchange clearances with hourly 1.5 percent dextrose dialysate exchanges
remain constant [7], the effect of instillation of intraperitoneal nitroprusside on
clearances was studied during eight consecutive exchanges after the sixth exchange
using two protocols. Each ofthe six patients was studied with both protocols within a
two-week period oftime. In Protocol A, 6 mg nitroprusside was added to exchanges
3-5 and no drug was added to exchanges 1-2 and 6-8 (Table 1). In Protocol B, 6 mg
nitroprusside was added to exchanges 3 to 8 and no drug was added to exchanges 1-2
(Table 1). Period II is defined as exchanges 3 to 5. The sixthexchange is regarded as a
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TABLE 1
Methods
Hour Dialysate Protocol A Protocol B Clearance Period
1 1.5% dextrose no drug no drug
2 1.5% dextrose no drug no drug
3 1.5% dextrose 6 mg nitroprusside 6 mg nitroprusside
4 1.5% dextrose 6 mg nitroprusside 6 mg nitroprusside
5 1.5% dextrose 6 mg nitroprusside 6 mg nitroprusside
6 1.5% dextrose no drug 6 mg nitroprusside washout
7 1.5% dextrose no drug 6 mg nitroprusside
8 1.5% dextrose no drug 6 mg nitroprusside
washout exchange. Period III is defined as exchanges 7 and 8. Mean clearances were
calculated for periods II and III.
Blood pressure and pulse were monitored every 20 minutes through the eight-hour
study protocols. No significant change in these parameters occurred in any patient.
Statistical analysis was performed by paired "t" testing.
RESULTS
Protocol A (Table 2)
Addition of intraperitoneal nitroprusside in exchanges 3-5 (period II) resulted in
significant (p < 0.001) increments in urea and B12 clearances and dialysate to plasma
solute ratios. Urea clearance increased 36 percent, and B12 clearance increased 37
TABLE 2
Protocol A
Patients
AB PC VG LS QP RC Mean±SEM
Urea clearance
Period 1 15.1 19.3 12.0 14.9 21.3 18.8 16.9± 1.4
Period 11 19.0 22.3 19.7 18.2 32.1 25.9 22.9 ± 2.2
Period III 13.2 21.5 15.3 14.6 23.0 21.4 18.1 ± 1.7
D/P* urea ratio
Period I .46 .55 .35 .41 .66 .52 .41 ±.08
Period 11 .53 .66 .50 .49 .88 .69 .63 ±.06
Period III .36 .51 .46 .40 .65 .56 .49±.04
B1,2 clearance
Period 1 6.0 6.9 2.7 3.4 11.6 6.7 6.2 1.3
Period 11 7.4 8.8 3.8 4.5 15.9 10.6 8.5 £ 1.8
Period III 5.3 7.4 3.8 3.4 10.6 7.4 6.3 ± 1.1
D/P B,2 ratios
Period I .17 .20 .07 .09 .36 .19 .18 ±.04
Period II .22 .26 .11 .12 .44 .29 .24 ±.05
Period III .15 .18 .11 .09 .31 .19 .17 ±.03
*D/P is dialysate to plasma ratio
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percent. After withdrawal of the nitroprusside (period III), urea and B,2 clearances
and dialysate to plasma solute ratios were no longer significantly different from
baseline values (period I).
Protocol B
Addition of nitroprusside to six consecutive exchanges resulted in a sustained
increased clearance level. Thus, as in protocol A, urea and inulin clearance and
dialysate to plasma solute ratios increased significantly (p <.001) in period II.
Continued addition of nitroprusside through exchange 6-8 (period III) did not result
in a further increase in clearances. Urea clearance remained about 25 ml/min and B12
clearance about 9 ml/min.
DISCUSSION
The present data demonstrate that addition of6 mgm ofnitroprusside to 2000 cc of
peritoneal dialysis solution can improve the efficiency of small and middle molecule
solute removal during a routine peritoneal dialysis. Continued use ofnitroprusside is
apparently necessary to sustain the increased rate ofsolute removal, since in protocol
A clearances during the exchanges following discontinuation of intraperitoneal
nitroprusside returned to baseline level. Administration ofintraperitoneal nitroprus-
side for six consecutive exchanges did not result in a further increment in clearances.
Treatment with intraperitoneal nitroprusside for six exchanges was well tolerated by
all six patients, with no significant changes in blood pressure or pulse occurring.
Whether more prolonged administration of intraperitoneal nitroprusside can be
safely achieved remains to be determined.
The mechanism by which intraperitoneal nitroprusside results in enhanced clear-
ances is not clear. Recent studies in which the micro circulation of rat cremaster
muscle bathed in peritoneal dialysis solution was studied demonstrated thataddition
of nitroprusside to the dialysis fluid established continuous perfusion of arterioles
TABLE 3
Protocol B
Patients
AB PC VG LS QP RC Mean ± SEM
Urea clearance
Period I 15.1 19.4 14.9 17.3 29.7 19.1 19.3 ±2.2
Period 11 20.7 29.7 20.0 21.4 34.2 25.4 25.2+ 2.2
Period III 22.4 26.2 19.3 21.1 35.1 24.1 24.7 t.2.3
D/P urea ratio
Period I .43 .57 .42 .49 .85 .59 .56 ±.06
Period I1 .59 .70 .54 .58 .99 .67 .68 ±.07
Period III .60 .69 .53 .57 .98 .67 .67 ±.07
B12 clearance
Period I 5.6 6.9 3.7 4.6 14.5 5.3 6.8 ± 1.6
Period 11 7.6 11.6 5.7 5.2 16.0 7.8 9.0± 1.7
Period III 8.8 9.4 7.6 5.0 16.3 7.6 9.1 + 1.6
D/P B 2 ratios
Period 1 .16 .20 .11 .12 .41 .16 .19 i .05
Period 11 .22 .28 .16 .14 .47 .22 .25±.05
Period III .24 .26 .21 .14 .48 .23 .26 ±.05
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that had been perfused either intermittently or not at all [14]. Thus, nitroprusside
may increase the endothelial area available for peritoneal transfer by increasing the
total area of arterioles and capillaries perfused. The proportional increment in small
and middle molecule clearances in response to intraperitoneal nitroprusside noted in
a rat model of peritoneal dialysis supports this hypothesis [4]. Similarly, in the
present study the increments in urea and B12 clearances were both about 35 percent.
However, the interpretation of this proportional increase is complicated by the
possible limitations imposed in the urea clearance by the dialysate flow rate of 33
ml/min.
Previous studies of Nolph et al. [14], in which the effects of intraperitoneal
nitroprusside on peritoneal dialysis clearances in patients were examined, reported an
increment of about 20 percent in small molecule clearances with the addition of the
vasodilator. However, clearances of inulin, which were determined in only one
patient, increased over 200 percent during the addition of 9 mg of nitroprusside to
nine consecutive two-liter exchanges. This large increase in the clearance of inulin
was associated with a 63 percent increment in the calculated mass transfercoefficient
for inulin. In the present study the percent increment in clearances of larger sized
molecules was not as marked as observed by Nolph. Differences between the present
study and Nolph's report include the measurement of vitamin B12 (MW = 1350)
clearances versus inulin (MW = 5200) clearances, and the dose of nitroprusside used
(6 mg versus 9 mg per two liters of dialysate).
The effect of intraperitoneal nitroprusside on urea and inulin peritoneal dialysis
clearances in the rat [4] is similar to that observed in the present study. The only
difference is that, in the rat model, the increased clearances persist during the three
exchanges following the discontinuation of nitroprusside administration. A major
difference between the rat and patient studies is the duration of each exchange: 15
minutes in the rat and 60 minutes in the patients. Perhaps the effect ofnitroprusside
on dilating capillaries and arterioles is of sufficient duration to cause persistently
increased clearances in the protocol used in the rat studies but not of sufficient
duration to result in increased clearances in period III of protocol A in the present
study.
In summary, the addition of 6 mg of nitroprusside to peritoneal dialysis solution
can result in a significant increment in small and middle molecule clearances.
Maintenance of the higher clearances requires sustained administration ofthe drug,
which can be tolerated for at least six exchanges with no adverse side effects.
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